Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma

The relevance of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Clinical trials targeting ER with selective estrogen receptor modulators in pancreatic cancer did not show any benefit.